Named on 3 rounds in the feed.
Rounds from 2025-01-10 to 2026-09-16
ROUNDS
3
led 1, joined 2
LED ROUNDS · USD
$40M
across 1 round · 1 co-led, split evenly
CO-INVESTORS
14
named beside it
Named on 3 rounds in the feed.
Rounds from 2025-01-10 to 2026-09-16
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Sling Therapeutics A biopharmaceutical company advancing oral linsitinib for thyroid eye disease | Series C Verified against 1 of 20 sources | $123M | 2026-09-16 | [ PART ] |
Odyssey Odyssey Therapeutics develops innovative therapies aimed at transforming the treatment of autoimmune and inflammatory diseases for patients. | Series D Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $213M | 2025-09-10 | [ PART ] |
Ouro Medicines Ouro Medicines develops treatments for immune-mediated diseases, targeting patients with such conditions. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-01-10 | [ LEAD ] |